Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06489665

Imaging Quality and Potential Clinical Relevance of Phase Contrast Mammography In-vivo: a Single-center, Prospective Study

Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Zurich - Diagnostic Radiology, Zurich, Canton of Zurich, Switzerland

Loading trial locations.

About this study

Category C2 Medicine product without CE label.

Objective(s):

Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography.

Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography.

Measurements and procedures:

Phase 0: Phase contrast mammography of the mastectomy, tumorectomy or breast biopsy samples is performed after breast surgery in addition to the standard clinical procedures Phase 1: Phase contrast mammography is performed before the operation in case of known breast carcinoma in addition to the standard clinical procedures Phase 2: Phase contrast mammography is performed directly in the clinical routine. The result is compared with the result of the conventional digital mammography and the ultrasound examination.

Number of Participants with Rationale:

Phase 0: expected to be 30 Phase 1: expected to be 20 Phase 2: expected to be 300 (correct number will be defined according to Phase 1)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion criteria -Phase 0:
  • >18 years
  • Mastectomy, tumorectomy or biopsy planned
  • Informed consent of the patient

Inclusion criteria

-Phase 1:

  • >18 years
  • BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy);
  • Scheduled for mastectomy or breast conserving surgery with radiotherapy.
  • Informed consent of the patient

Inclusion criteria

- Phase 2:

  • >40 years
  • undergoing mammography for screening or diagnostic purpose.
  • Informed consent of the patient

Exclusion criteria

  • Exclusion criteria for all three Phases:
  • Breast implants. The women will be asked, if they have a breast-implant.
  • Inability to understand the study procedure due to cognitive or linguistic deficits.

Exclusion criteria

for patients, participating in Phase 1 and Phase 2:

  • Pregnancy
  • Breast-feeding.
  • Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months

Treatment and study plan

Experimental Intervention

Diagnostic Test

Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Other names: control intervention

Primary outcomes

  1. Sensitivity and specificity of PCM compared to FFDM represent the primary outcome since the limited sensitivity of mammography, in particular in patients with dense breasts, represents the major limitation of the currently applied FFDM.

    Time frame: 30 month

    The standard reference will be the histologic specimen after biopsy

Secondary outcomes

  1. Lesion extent will be estimated using both PCM and FFDM. Pathological measurements obtained from the surgical specimen will be used as standard of reference.

    Time frame: 30 month

    The aim is to evaluate if PCM, due to the expected improved visibility of the lesions, can allow for a better estimation of lesion extent with subsequent benefit on the preoperative planning.

Study contacts

Contact information is provided by the study sponsor or research team.

Judith Jehle

CONTACT

[email protected]

0763257051

Thomas Frauenfelder, Prof

CONTACT

[email protected]

+41 44 255 93 83

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland
  • GratXray AG

Registry information

Official study title

Imaging Quality and Potential Clinical Relevance of Phase Contrast

Important dates

Study start
2024
Primary completion
2029
Study completion
2030
First posted
Jul 8, 2024
Registry last updated
Feb 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.